Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models.
Surgical management of malignant cerebral edema secondary to immune reconstitution inflammatory syndrome from natalizumab-associated progressive multifocal encephalopathy.
Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells.
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
Association between pathological and MRI findings in multiple sclerosis.
Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice.
Imaging of the spine at 3 tesla.
Can smoking aggravate my multiple sclerosis symptoms?
Neurorehabilitation for other neurologic disorders.
Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.
Coping strategies and mood profiles in patients with multiple sclerosis.
A palliative care hotline for multiple sclerosis: A pilot feasibility study.
Simvastatin: two decades in a circle.
Riluzole increases glutamate uptake by cultured C6 astroglial cells.
Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study.
Cyclophosphamide therapy in pediatric multiple sclerosis.
Modeling the heterogeneity of multiple sclerosis in animals.
[Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal.]
Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
FTY720, sphingosine 1-phosphate receptor modulator, selectively radioprotects hippocampal neural stem cells.
Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination.
Disclosing the diagnosis of multiple sclerosis: The Profile Project.
Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Evaluating medically at-risk drivers: a survey of assessment practices in Canada.

Pages